Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Genomic Epidemiology Data Infrastructure Needs for SARS-CoV-2
In December 2019, new cases of severe pneumonia were first detected in Wuhan, China, and the cause was determined to be a novel beta coronavirus related to the severe acute respiratory syndrome (SARS) coronavirus that emerged from a bat reservoir in 2002. Within six months, this new virusâ€"SARS coronavirus 2 (SARS-CoV-2)â€"has spread worldwide, infecting at least 10 million people with an estimated 500,000 deaths. COVID-19, the disease caused by SARS-CoV-2, was declared a public health emergency of international concern on January 30, 2020 by the World Health Organization (WHO) and a pandemic on March 11, 2020. To date, there is no approved effective treatment or vaccine for COVID-19,...
Framework for Equitable Allocation of COVID-19 Vaccine
In response to the coronavirus disease 2019 (COVID-19) pandemic and the societal disruption it has brought, national governments and the international community have invested billions of dollars and immense amounts of human resources to develop a safe and effective vaccine in an unprecedented time frame. Vaccination against this novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), offers the possibility of significantly reducing severe morbidity and mortality and transmission when deployed alongside other public health strategies and improved therapies. Health equity is intertwined with the impact of COVID-19 and there are certain populations that are at increased...
Evolution of SARS-CoV-2: impact of variants on hosts, COVID-19 vaccines and countermeasures
The ‘novel coronavirus disease’ (COVID-19) has caused significant global morbidity, mortality and economic damage on a scale similar to the influenza pandemic of 1918. The causative ‘severe acute respiratory syndrome virus 2’ (SARS-CoV-2) is a RNA virus which is evolving rapidly, accumulating mutations, and existing as a cloud of variants with quasispecies diversity. We have tens of thousands of variants, of which currently two are ‘variants of interest’ (Lambda, Mu) and another four ‘variants of concern’ (Alpha, Beta, Gamma, Delta, Omicron) to the World Health Organization (WHO). Variants of interest often emerge as variants under investigation in one or more countries, as s...
Accelerating access to genomics for global health
This publication presents the recommendations of the WHO Science Council to the Director-General on accelerating access to genomics for global health. A series of workshops was held in 2021 to gather information and perspectives on this topic. Fifteen actions are recommended to achieve the goal of accelerating access to genomics for global health.
